Photocure ASA: Daniel Schneider appointed Chief Executive Officer

Oslo, Norway, 20 September 2018: Photocure ASA (OSE: PHO), announces today that
Daniel Schneider has been appointed President and Chief Executive Officer of
Photocure. Mr Schneider joins Photocure from the position of General Manager for
Ablynx N.V. in North America.

"I am pleased to announce Dan Schneider as our new President and Chief Executive
Officer. Photocure is entering a period of accelerated growth in the important
U.S. market with strengthened focus on commercial development. Dan brings over
25 years of experience in developing and expanding rapidly growing healthcare
companies in the U.S. He will further leverage on the opportunities arising from
Photocure's unique position in the bladder cancer market. I look forward working
with Dan to develop Photocure into becoming the leading bladder cancer company",
says Jan H. Egberts, M.D. Chairman of the Board.

Mr Schneider is a U.S. citizen and holds an MBA from Washington University and a
Bachelor of Science degree in Business Administration from St. Louis University
with a double major in Finance and Marketing. Mr Schneider brings extensive
commercial experience from the U.S. healthcare industry, including his previous
position as General Manager for Ablynx N.V. in North America. Mr Schneider has
also held executive management positions in other pharmaceutical and biotech
companies, including BTG International, Somaxon Pharmaceuticals and Sepracor.

"The Photocure team has built a unique company within the field of bladder
cancer, with excellent people, world leading technology and high-potential
products. The company has developed a solid infrastructure in key regions,
especially in the U.S. We will continue to scale and leverage on this growth
platform to deliver on the commercial opportunities in the bladder cancer
markets. I look forward to work with the team to expand the commercial footprint
and to embark on the growth journey for Photocure", says Mr Schneider.

Mr Schneider will commence the position upon further agreement, expected prior
to 1 November 2018. Erik Dahl will continue to serve as the acting Chief
Executive Officer until Mr Schneider's commencement of his position, after which
Mr Dahl will resume his previous role as the Chief Financial Officer of
Photocure.


For further information, please contact:

Photocure
Jan H. Egberts
Chairperson of the Board
Tel: +31 614672518
Email: janegberts@aol.com


Notes to editors

About Photocure ASA
Photocure, The Bladder Cancer Company, delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, which makes
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). The US headquarters for Photocure Inc., are in
Princeton, New Jersey. For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.